124 related articles for article (PubMed ID: 34032770)
1. Argon plasma coagulation with atezolizumab and chemoradiation in lung pleomorphic cancer showed a remarkable response: Case report.
Harada M; Morikawa K; Kagoo N; Ito Y; Kubota T; Ichijo K; Mochizuki E; Uehara M; Matsuura S; Yasuda K; Tsukui M; Koshimizu N
Medicine (Baltimore); 2021 May; 100(21):e26149. PubMed ID: 34032770
[TBL] [Abstract][Full Text] [Related]
2. A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer.
Yin J; Dong J; Gao W; Wang Y
Medicine (Baltimore); 2018 Nov; 97(44):e13112. PubMed ID: 30383701
[TBL] [Abstract][Full Text] [Related]
3. Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.
Yorozuya T; Taya T; Yasuda K; Nagano Y; Shioya M; Chiba H; Takahashi H
Thorac Cancer; 2020 Apr; 11(4):1090-1093. PubMed ID: 32045109
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
5. [Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1 expression].
Roulleaux Dugage M; Brosseau S
Bull Cancer; 2021 Oct; 108(10):904-906. PubMed ID: 34598788
[No Abstract] [Full Text] [Related]
6. Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies.
Qian J; Nie W; Lu J; Zhang L; Zhang Y; Zhang B; Wang S; Hu M; Xu J; Lou Y; Dong Y; Niu Y; Yan B; Zhong R; Zhang W; Chu T; Zhong H; Han B
Int J Cancer; 2020 Jun; 146(11):3124-3133. PubMed ID: 31583695
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer.
Ramagopalan S; Gupta A; Arora P; Thorlund K; Ray J; Subbiah V
JAMA Netw Open; 2021 Nov; 4(11):e2134299. PubMed ID: 34767024
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
[TBL] [Abstract][Full Text] [Related]
10. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Gandara D; Reck M; Moro-Sibilot D; Mazieres J; Gadgeel S; Morris S; Cardona A; Mendus D; Ballinger M; Rittmeyer A; Peters S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737340
[TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.
Furuya N; Nishino M; Wakuda K; Ikeda S; Sato T; Ushio R; Tanzawa S; Sata M; Ito K
Thorac Cancer; 2021 Mar; 12(5):613-618. PubMed ID: 33448648
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy.
Matsubara T; Takamori S; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Seto T; Okamoto T
Thorac Cancer; 2021 Dec; 12(23):3286-3289. PubMed ID: 34689423
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
Hopkins AM; Kichenadasse G; McKinnon RA; Abuhelwa AY; Logan JM; Badaoui S; Karapetis CS; Rowland A; Sorich MJ
Br J Cancer; 2022 Jan; 126(1):42-47. PubMed ID: 34711947
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience.
Wee CE; Costello BA; Orme JJ; Quevedo JF; Pagliaro LC
Prostate; 2021 Sep; 81(13):938-943. PubMed ID: 34254332
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Yamamoto N; Harada H; Okamoto I; Masuda N; Hayakawa K; Satouchi M; Soejima T; Nishio M; Kozuka T; Takeda K; Tanaka M; Seto T; Sasaki T; Tsubouchi H; Kakurai Y; Nishimura Y; Nakagawa K
Clin Lung Cancer; 2021 Mar; 22(2):134-141. PubMed ID: 33518480
[TBL] [Abstract][Full Text] [Related]
17. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy and Immunotherapy Combinations for Lung Cancer.
Agrawal V; Benjamin KT; Ko EC
Curr Oncol Rep; 2020 Nov; 23(1):4. PubMed ID: 33215306
[TBL] [Abstract][Full Text] [Related]
19. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
[TBL] [Abstract][Full Text] [Related]
20. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
[No Abstract] [Full Text] [Related]
[Next] [New Search]
